Oversubscribed Series C led by S32 with backing from NVIDIA and others

由S32领投，英伟达等机构跟投的超额认购C轮融资

Funding will advance a pipeline of EDEN-designed therapeutics, starting with

资金将推动一系列由EDEN设计的治疗药物的研发进程，始于

in vivo

体内

cell therapy, and expand pharmaceutical partnerships

细胞疗法，并拓展制药合作伙伴关系

The company has demonstrated strong preclinical results across multiple modalities and disease areas

该公司在多种技术平台和疾病领域均展现出强劲的临床前研究结果

LONDON and BOSTON

伦敦和波士顿

,

，

Sept. 23, 2026

2026年9月23日

/PRNewswire/ -- Basecamp Research, a frontier AI company developing AI-designed medicines, today announced a $140M Series C financing to train a new generation of EDEN models and advance a pipeline of AI-designed therapeutics towards clinical development.

/美通社/ -- 前沿人工智能公司Basecamp Research致力于开发由AI设计的药物，今日宣布完成1.4亿美元C轮融资，用于训练新一代EDEN模型，并推动一系列AI设计的治疗药物向临床开发阶段迈进。

Basecamp's ambition is to develop cures for diseases that remain incurable by designing medicines that reprogram the body to repair itself. The company combines frontier AI models trained on proprietary biological data with technology for writing DNA sequences into cells.

Basecamp 的雄心是通过设计能够重编程身体以实现自我修复的药物，开发出针对目前仍无法治愈疾病的疗法。该公司将基于专有生物数据训练的前沿人工智能模型与将 DNA 序列写入细胞的技术相结合。

Continue Reading

继续阅读

Basecamp Research team and biodiversity data partners in Malawi

Basecamp研究团队及马拉维生物多样性数据合作伙伴

Basecamp Research translation lab in Kendall Square, Cambridge, MA

位于马萨诸塞州剑桥市肯德尔广场的 Basecamp Research 翻译实验室

'We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how,'

“我们相信，医学的未来在于对机体进行重编程，使其能够自我修复。我们设计模型和药物，以教导机体如何实现这一过程。”

said Glen Gowers, co-founder and CEO of Basecamp Research.

Basecamp Research 联合创始人兼首席执行官 Glen Gowers 表示。

'AI-based approaches promise to change what's possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most.'

基于人工智能的方法有望为目前选择有限的患者带来新的治疗可能。这笔资助将使这项技术更贴近最需要的患者群体。

The oversubscribed round was led by S32, with participation from Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures..

本轮超额认购由 S32 领投，Anthropic 的 Anthology Fund、Catalio Capital Management、European Tech Collective、Firebrand River Capital、Inception Fund、King Philanthropies、NATO Innovation Fund、英伟达（NVIDIA）、PostScriptum、Redalpine、洛克菲勒基金会（The Rockefeller Foundation）、Singular、Sovereign AI 以及 True Ventures 参与投资。

Additional investment comes from senior leaders from across pharma, biotech, and global industry, including André Hoffmann, Vice-Chairman of Roche, who said:

额外投资来自制药、生物科技和全球行业的高层领导，包括罗氏副董事长安德烈·霍夫曼，他表示：

'The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalised, AI-designed therapeutics represent the next transformation of that journey. Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies.

五十年前开始的生物技术革命改变了我们制造药物的方式。个性化、由人工智能设计的治疗方案代表了这一进程中的下一次变革。Basecamp Research 已经构建了实现这一目标的完整平台，涵盖从生物数据到训练模型再到设计疗法的全流程。

This will be key in helping the industry to continue to innovate.' .

这将是帮助行业持续创新的关键。

Applying EDEN to develop new therapies

应用EDEN开发新疗法

Basecamp Research is applying EDEN, its biological foundation model, to

Basecamp Research 正在将其生物基础模型 EDEN 应用于

in vivo

体内

cell therapy – reprogramming a patient's cells inside the body. Today's cell therapies are limited both in the complexity of what they can deliver and by a manufacturing process that costs hundreds of thousands of dollars per patient.

细胞疗法——在患者体内对其细胞进行重编程。目前的细胞疗法既受限于其所能实现功能的复杂性，也受限于每位患者高达数十万美元的生产成本。

By pairing EDEN's ability to design long and complex DNA sequences with large serine recombinases that can precisely integrate them into the genome, Basecamp's platform aims to underpin the future of cell therapies, making them more sophisticated, more customisable and simpler to administer. This has the potential to transform how we treat cancer, autoimmune disease, and more..

通过将EDEN设计长而复杂DNA序列的能力与能够将其精确整合到基因组中的大型丝氨酸重组酶相结合，Basecamp的平台旨在为细胞疗法的未来奠定基础，使其更加精密、更具可定制性且更易于施用。这有望变革我们治疗癌症、自身免疫性疾病等疾病的方式。

The company has demonstrated strong preclinical results across multiple modalities and disease areas. To expand its pharmaceutical partnerships, Basecamp has appointed Richard Pearce, formerly of Biogen, as Chief Business Officer.

该公司在多种技术平台和疾病领域均展现出强劲的临床前研究结果。为拓展制药合作伙伴关系，Basecamp 已任命前渤健（Biogen）高管理查德·皮尔斯（Richard Pearce）担任首席商务官。

Andy Conrad, General Partner at S32 and former CEO of Google's Verily, who joins the Board of Directors, said:

S32 普通合伙人、前 Google Verily 首席执行官安迪·康拉德（Andy Conrad）在加入董事会时表示：

'AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health. The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people's lives.

人工智能正在为社会各个领域开辟新的可能性，但或许在人类健康领域，其潜力最具意义。将人工智能、生物数据与科学洞见相结合的能力，有望变革我们理解疾病、发现药物的方式，并最终改善和延长人们的生命。

Basecamp Research is building an important technology platform at the center of that opportunity.'.

Basecamp Research 正在这一机遇的核心构建一个重要的技术平台。

The AI and data powering Basecamp Research's therapies

支撑Basecamp Research疗法的AI与数据

At the centre of Basecamp Research's AI platform is the Trillion Gene Atlas, the world's largest proprietary biological AI training dataset. Built with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics, the Atlas draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents..

Basecamp Research人工智能平台的核心是“万亿基因图谱”（Trillion Gene Atlas），这是全球最大的专有生物人工智能训练数据集。该图谱由Basecamp Research与英伟达（NVIDIA）、Anthropic、PacBio和Ultima Genomics等合作伙伴共同构建，其数据来源于通过获取与惠益分享伙伴关系在遍布七大洲的30多个国家收集的生物数据。

Trained on this data, the company's EDEN models recognise patterns across a huge breadth of previously unseen biology. Unlike AI systems developed for a single scientific task, EDEN models aim to deliver a universal understanding of how DNA works across all of life.

基于这些数据训练，该公司的EDEN模型能够识别海量前所未见的生物数据中的模式。与为单一科学任务开发的人工智能系统不同，EDEN模型旨在提供对DNA在所有生命体中运作方式的普适性理解。

This means that the models can generate potential therapeutic candidates directly from information about a disease, an approach already demonstrated through Basecamp's collaboration with Anthropic on Claude Science. The EDEN models' capabilities include designing cell and gene therapies, enzymes and peptides..

这意味着，这些模型能够直接根据疾病信息生成潜在的治疗候选方案，这一方法已通过Basecamp与Anthropic在Claude Science项目上的合作得到验证。EDEN模型的能力包括设计细胞和基因疗法、酶以及肽类分子。

About Basecamp Research

关于 Basecamp Research

Basecamp Research trains frontier AI models for therapeutic design. The EDEN models are trained on the Trillion Gene Atlas, the world's largest proprietary genomic dataset, collected through partnerships in more than 30 countries worldwide. Its pipeline of EDEN-designed therapeutics, beginning with .

Basecamp Research 训练用于药物设计的前沿人工智能模型。EDEN 模型基于“万亿基因图谱”进行训练，这是全球最大的专有基因组数据集，通过与全球30多个国家的合作伙伴关系收集而来。其由 EDEN 设计的药物研发管线，始于

in vivo

体内

cell therapy, is advancing towards clinical development. Basecamp Research is headquartered in London with offices and labs in Cambridge, MA.

细胞疗法正朝着临床开发方向推进。Basecamp Research 总部位于伦敦，并在马萨诸塞州剑桥市设有办公室和实验室。

SOURCE Basecamp Research

来源：Basecamp Research

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示